A citation-based method for searching scientific literature

Ronglai Shen, Michael A Postow, Matthew Adamow, Arshi Arora, Margaret Hannum, Colleen Maher, Phillip Wong, Michael A Curran, Travis J Hollmann, Liwei Jia, Hikmat Al-Ahmadie, Niamh Keegan, Samuel A Funt, Gopa Iyer, Jonathan E Rosenberg, Dean F Bajorin, Paul B Chapman, Alexander N Shoushtari, Allison S Betof, Parisa Momtaz, Taha Merghoub, Jedd D Wolchok, Katherine S Panageas, Margaret K Callahan. Sci Transl Med 2021
Times Cited: 16







List of co-cited articles
101 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, Paolo A Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J Gogas, Christopher D Lao, Juliana Janoski De Menezes,[...]. N Engl J Med 2022
73
37

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
31

LAG-3: from molecular functions to clinical applications.
Takumi Maruhashi, Daisuke Sugiura, Il-Mi Okazaki, Taku Okazaki. J Immunother Cancer 2020
77
25

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. J Clin Oncol 2022
44
25

Metalloproteases regulate T-cell proliferation and effector function via LAG-3.
Nianyu Li, Yao Wang, Karen Forbes, Kate M Vignali, Bret S Heale, Paul Saftig, Dieter Hartmann, Roy A Black, John J Rossi, Carl P Blobel,[...]. EMBO J 2007
144
25

LAG-3, a novel lymphocyte activation gene closely related to CD4.
F Triebel, S Jitsukawa, E Baixeras, S Roman-Roman, C Genevee, E Viegas-Pequignot, T Hercend. J Exp Med 1990
473
25

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Jun Wang, Miguel F Sanmamed, Ila Datar, Tina Tianjiao Su, Lan Ji, Jingwei Sun, Ling Chen, Yusheng Chen, Gefeng Zhu, Weiwei Yin,[...]. Cell 2019
312
25

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo, Meghan E Turnis, Monica V Goldberg, Jaishree Bankoti, Mark Selby, Christopher J Nirschl, Matthew L Bettini, David M Gravano, Peter Vogel, Chih Long Liu,[...]. Cancer Res 2012
926
25

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells.
Theodore Kouo, Lanqing Huang, Alexandra B Pucsek, Minwei Cao, Sara Solt, Todd Armstrong, Elizabeth Jaffee. Cancer Immunol Res 2015
231
25

PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M Sholl, Keith M Kerr, Sacha Gnjatic, Ignacio I Wistuba, David L Rimm, Ming Sound Tsao, Fred R Hirsch. Nat Rev Clin Oncol 2021
157
25

Tim-3 finds its place in the cancer immunotherapy landscape.
Nandini Acharya, Catherine Sabatos-Peyton, Ana Carrizosa Anderson. J Immunother Cancer 2020
102
18

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
18

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo. Mol Cancer 2019
379
18

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
579
18

B cells are associated with survival and immunotherapy response in sarcoma.
Florent Petitprez, Aurélien de Reyniès, Emily Z Keung, Tom Wei-Wu Chen, Cheng-Ming Sun, Julien Calderaro, Yung-Ming Jeng, Li-Ping Hsiao, Laetitia Lacroix, Antoine Bougoüin,[...]. Nature 2020
607
18

Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Rita Cabrita, Martin Lauss, Adriana Sanna, Marco Donia, Mathilde Skaarup Larsen, Shamik Mitra, Iva Johansson, Bengt Phung, Katja Harbst, Johan Vallon-Christersson,[...]. Nature 2020
571
18

B cells and tertiary lymphoid structures promote immunotherapy response.
Beth A Helmink, Sangeetha M Reddy, Jianjun Gao, Shaojun Zhang, Rafet Basar, Rohit Thakur, Keren Yizhak, Moshe Sade-Feldman, Jorge Blando, Guangchun Han,[...]. Nature 2020
699
18

Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.
Sara Valpione, Elena Galvani, Joshua Tweedy, Piyushkumar A Mundra, Antonia Banyard, Philippa Middlehurst, Jeff Barry, Sarah Mills, Zena Salih, John Weightman,[...]. Nat Cancer 2020
71
18


Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo.
Nicholas M Durham, Christopher J Nirschl, Christopher M Jackson, Jimmy Elias, Christina M Kochel, Robert A Anders, Charles G Drake. PLoS One 2014
87
18

Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation.
Takeo K Maeda, Daisuke Sugiura, Il-Mi Okazaki, Takumi Maruhashi, Taku Okazaki. J Biol Chem 2019
28
18

Role of LAG-3 in regulatory T cells.
Ching-Tai Huang, Creg J Workman, Dallas Flies, Xiaoyu Pan, Aimee L Marson, Gang Zhou, Edward L Hipkiss, Sowmya Ravi, Jeanne Kowalski, Hyam I Levitsky,[...]. Immunity 2004
787
18

LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses.
Feng Xu, Jing Liu, Di Liu, Biao Liu, Min Wang, Zhiyuan Hu, Xuemei Du, Li Tang, Fuchu He. Cancer Res 2014
173
18



LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII.
Takumi Maruhashi, Il-Mi Okazaki, Daisuke Sugiura, Suzuka Takahashi, Takeo K Maeda, Kenji Shimizu, Taku Okazaki. Nat Immunol 2018
87
18

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
Ruea-Yea Huang, Cheryl Eppolito, Shashikant Lele, Protul Shrikant, Junko Matsuzaki, Kunle Odunsi. Oncotarget 2015
155
18

LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes.
Qianxia Zhang, Maria Chikina, Andrea L Szymczak-Workman, William Horne, Jay K Kolls, Kate M Vignali, Daniel Normolle, Maria Bettini, Creg J Workman, Dario A A Vignali. Sci Immunol 2017
60
18

Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.
Xiaobo Mao, Michael Tianhao Ou, Senthilkumar S Karuppagounder, Tae-In Kam, Xiling Yin, Yulan Xiong, Preston Ge, George Essien Umanah, Saurav Brahmachari, Joo-Ho Shin,[...]. Science 2016
377
18

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.
Victoria Atkinson, Adnan Khattak, Andrew Haydon, Melissa Eastgate, Amitesh Roy, Prashanth Prithviraj, Christian Mueller, Chrystelle Brignone, Frederic Triebel. J Immunother Cancer 2020
23
18

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn,[...]. Science 2018
944
18

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
12

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Georgina V Long, Reinhard Dummer, Omid Hamid, Thomas F Gajewski, Christian Caglevic, Stephane Dalle, Ana Arance, Matteo S Carlino, Jean-Jacques Grob, Tae Min Kim,[...]. Lancet Oncol 2019
387
12

TIGIT in cancer immunotherapy.
Joe-Marc Chauvin, Hassane M Zarour. J Immunother Cancer 2020
149
12

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy.
Claudia Trojaniello, Jason J Luke, Paolo A Ascierto. Front Oncol 2021
10
20

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
Praveen K Bommareddy, Anand Patel, Saamia Hossain, Howard L Kaufman. Am J Clin Dermatol 2017
126
12


High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
D J McGrail, P G Pilié, N U Rashid, L Voorwerk, M Slagter, M Kok, E Jonasch, M Khasraw, A B Heimberger, B Lim,[...]. Ann Oncol 2021
199
12


Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, Justin Saco, Helena Escuin-Ordinas, Gabriel Abril Rodriguez, Jesse M Zaretsky, Lu Sun, Willy Hugo, Xiaoyan Wang,[...]. Cell Rep 2017
762
12

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison. Cancer Discov 2018
12

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C Cappelli, Frank B Cortazar, David E Gerber, Lamya Hamad, Eric Hansen, Douglas B Johnson,[...]. J Immunother Cancer 2021
73
12

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
12

Regulatory T cells in cancer immunotherapy.
Atsushi Tanaka, Shimon Sakaguchi. Cell Res 2017
712
12

Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.
Simon Eschweiler, James Clarke, Ciro Ramírez-Suástegui, Bharat Panwar, Ariel Madrigal, Serena J Chee, Ioannis Karydis, Edwin Woo, Aiman Alzetani, Somaia Elsheikh,[...]. Nat Immunol 2021
14
14

Tertiary lymphoid structures in the era of cancer immunotherapy.
Catherine Sautès-Fridman, Florent Petitprez, Julien Calderaro, Wolf Herman Fridman. Nat Rev Cancer 2019
409
12

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A Akbay, Yvonne Y Li, Grit S Herter-Sprie, Kevin A Buczkowski, William G Richards, Leena Gandhi, Amanda J Redig, Scott J Rodig, Hajime Asahina,[...]. Nat Commun 2016
839
12

Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Qinchuan Wang, Jinhua Zhang, Huakang Tu, Dong Liang, David W Chang, Yuanqing Ye, Xifeng Wu. J Immunother Cancer 2019
53
12

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus, William H Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M Salay, Tracee L McMiller,[...]. J Clin Oncol 2010
12

Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
Lawrence P Andrews, Ashwin Somasundaram, Jessica M Moskovitz, Andrea L Szymczak-Workman, Chang Liu, Anthony R Cillo, Huang Lin, Daniel P Normolle, Kelly D Moynihan, Ichiro Taniuchi,[...]. Sci Immunol 2020
13
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.